Liberty Wealth Management’s Sonoma Pharmaceuticals SNOA Stock Holding History

Liberty Wealth Management’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-209	Closed	-$33K	–	967
2019 Q2	$33K	Buy	+209	New	+$32.1K	0.03%	326

Other funds holding SNOA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Liberty Wealth Management's SNOA Position: Q3 2019 in Review

Liberty Wealth Management sold out of Sonoma Pharmaceuticals (SNOA) in Q3 2019, closing a stake of 209 shares — an estimated $33K sold.

Liberty Wealth Management first reported a position in SNOA in Q2 2019 and held it in 1 quarter. The position peaked at $33K in Q2 2019. 13 funds tracked by Wall St. Rank hold SNOA as of Q3 2019.

Liberty Wealth Management reported no remaining Sonoma Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Liberty Wealth Management sold 209 Sonoma Pharmaceuticals shares in Q3 2019, an estimated $33K.
Liberty Wealth Management first reported a position in Sonoma Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Liberty Wealth Management's Sonoma Pharmaceuticals position peaked at $33K in Q2 2019.
13 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2019.

Based on Liberty Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.